A BILL 
To amend the Federal Food, Drug, and Cosmetic Act with 
respect to limitations on exclusive approval or licensure 
of orphan drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Fairness in Orphan 
4
Drug Exclusivity Act’’. 
5
04:53 Apr 30, 2021
H1629
2 
•HR 1629 IH
SEC. 2. LIMITATIONS ON EXCLUSIVE APPROVAL OR LICEN-
1
SURE OF ORPHAN DRUGS. 
2
(a) IN GENERAL.—Section 527 of the Federal Food, 
3
Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended— 
4
(1) in subsection (a), by striking ‘‘Except as 
5
provided in subsection (b)’’ and inserting ‘‘Except as 
6
provided in subsection (b) or (f)’’; and 
7
(2) by adding at the end the following: 
8
‘‘(f) LIMITATIONS ON EXCLUSIVE APPROVAL, CER-
9
TIFICATION, OR LICENSE.— 
10
‘‘(1) IN
GENERAL.—For a drug designated 
11
under section 526 for a rare disease or condition 
12
pursuant to the criteria set forth in subsection 
13
(a)(2)(B) of such section, the Secretary shall not 
14
grant, recognize, or apply exclusive approval or licen-
15
sure under subsection (a), and, if such exclusive ap-
16
proval or licensure has been granted, recognized, or 
17
applied, shall revoke such exclusive approval or licen-
18
sure, unless the sponsor of the application for such 
19
drug demonstrates— 
20
‘‘(A) with respect to an application ap-
21
proved or a license issued after the date of en-
22
actment of this subsection, upon such approval 
23
or issuance, that there is no reasonable expecta-
24
tion at the time of such approval or issuance 
25
that the cost of developing and making avail-
26
04:53 Apr 30, 2021
H1629
3 
•HR 1629 IH
able in the United States such drug for such 
1
disease or condition will be recovered from sales 
2
in the United States of such drug, taking into 
3
account all sales made or reasonably expected 
4
to be made within 12 years of first marketing 
5
the drug; or 
6
‘‘(B) with respect to an application ap-
7
proved or a license issued on or prior to the 
8
date of enactment of this subsection, not later 
9
than 60 days after such date of enactment, that 
10
there was no reasonable expectation at the time 
11
of such approval or issuance that the cost of de-
12
veloping and making available in the United 
13
States such drug for such disease or condition 
14
would be recovered from sales in the United 
15
States of such drug, taking into account all 
16
sales made or reasonably expected to be made 
17
within 12 years of first marketing the drug. 
18
‘‘(2) CONSIDERATIONS.—For purposes of sub-
19
paragraphs (A) and (B) of paragraph (1), the Sec-
20
retary and the sponsor of the application for the 
21
drug designated for a rare disease or condition de-
22
scribed in such paragraph shall consider sales from 
23
all drugs that— 
24
04:53 Apr 30, 2021
H1629
4 
•HR 1629 IH
‘‘(A) are developed or marketed by the 
1
same sponsor or manufacturer of the drug (or 
2
a licensor, predecessor in interest, or other re-
3
lated entity to the sponsor or manufacturer); 
4
and 
5
‘‘(B) are covered by the same designation 
6
under section 526. 
7
‘‘(3) CRITERIA.—No drug designated under 
8
section 526 for a rare disease or condition pursuant 
9
to the criteria set forth in subsection (a)(2)(B) of 
10
such section shall be eligible for exclusive approval 
11
or licensure under this section unless it met such 
12
criteria under such subsection on the date on which 
13
the drug was approved or licensed.’’. 
14
(b) RULE
OF CONSTRUCTION.—The amendments 
15
made in subsection (a) shall apply to any drug that has 
16
been or is hereafter designated under section 526 of the 
17
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb) 
18
for a rare disease or condition pursuant to the criteria 
19
under subsection (a)(2)(B) of such section regardless of— 
20
(1) the date on which such drug is designated 
21
or becomes the subject of a designation request 
22
under such section; 
23
(2) the date on which such drug is approved 
24
under section 505 of such Act (21 U.S.C. 355) or 
25
04:53 Apr 30, 2021
H1629
5 
•HR 1629 IH
licensed under section 351 of the Public Health 
1
Service Act (42 U.S.C. 262) or becomes the subject 
2
of an application for such approval or licensure; and 
3
(3) the date on which such drug is granted ex-
4
clusive approval or licensure under section 527 of 
5
the Federal Food, Drug, and Cosmetic Act (21 
6
U.S.C. 360cc) or becomes the subject of a request 
7
for such exclusive approval or licensure. 
8
SEC. 3. DETERMINATION OF BUDGETARY EFFECTS. 
9
The budgetary effects of this Act, for the purpose of 
10
complying with the Statutory Pay-As-You-Go Act of 2010, 
11
shall be determined by reference to the latest statement 
12
titled ‘‘Budgetary Effects of PAYGO Legislation’’ for this 
13
Act, submitted for printing in the Congressional Record 
14
by the Chairman of the House Budget Committee, pro-
15
vided that such statement has been submitted prior to the 
16
vote on passage. 
17
Æ 
04:53 Apr 30, 2021
H1629
